29th Jun 2006 16:03
GlaxoSmithKline PLC29 June 2006 Issued - 29 June 2006 London GlaxoSmithKline plc Announces Change to the Board of Directors GlaxoSmithKline plc (GSK) announces that Dr Daniel Podolsky has been appointedas a Non-Executive Director and will join the Board of the Company with effectfrom 1st July 2006. Dr Podolsky is Mallinkrodt Professor of Medicine and Chief of Gastroenterologyat Massachusetts General Hospital and Harvard Medical School as well as ChiefAcademic Officer of Partners HealthCare System. In commenting on the new appointment, Sir Christopher Gent, Chairman of GSK,said: "I am delighted that Dr Podolsky has agreed to join the Board. In addition tofulfilling the usual responsibilities of a non-executive director, Dan willspend time within our research and development organisation and, with hisexperience, will provide valuable insights to scientific developments outsideGSK." In addition, the Board has appointed Dr Podolsky and Tom de Swaan as members ofthe Corporate Responsibility Committee. Dr Podolsky's biographical details are given below together with a table showingthe membership of the Board and its Committees with effect from 1st July 2006. Simon BicknellCompany Secretary 29 June 2006 Notes The Board has determined that Dr Podolsky is independent in accordance with theCombined Code on Corporate Governance. Biographical details Dr Daniel Podolsky Age 53. Dr Podolsky is a world-renowned researcher who has advanced knowledgeof underlying mechanisms of disease and new therapies for gastrointestinaldisorders. He is also an international authority on trefoil proteins and innateimmunity. Dr. Podolsky has published and patented widely in his field. He ispast editor-in-chief of Gastroenterology, the leading journal in the field, andis immediate Past President of the American Gastroenterological Association. Dr Podolsky is also Chairman of the Board & Scientific Co-Founder of the GICompany a privately held, specialty biopharmaceutical company established tomeet the clinical needs and commercial opportunities available in the field ofgastrointestinal medicine. Board and Committee Membership with effect from 1st July 2006 Sir Christopher Gent Chairman Sir Ian Prosser Senior Independent Non-Executive Director Dr J-P Garnier Chief Executive Officer Mr J S Heslop Chief Financial Officer Dr Moncef Slaoui Executive Director, Chairman, Research & Development Dr Daniel Podolsky Independent Non-Executive Director Mr H Lawrence Culp Independent Non-Executive Director Sir Crispin Davis Independent Non-Executive Director Sir Deryck Maughan Independent Non-Executive Director Dr Ronaldo Schmitz Independent Non-Executive Director Mr Tom de Swaan Independent Non Executive Director Sir Robert Wilson Independent Non-Executive Director Board Committee Committee Chairman Members Audit Dr Ronaldo Schmitz* Sir Deryck Maughan Sir Ian Prosser Mr Tom de Swaan* Sir Robert Wilson Remuneration Sir Robert Wilson Mr H Lawrence Culp Sir Crispin Davis Dr Ronaldo Schmitz Nominations Sir Christopher Gent Sir Ian Prosser Dr Ronaldo Schmitz Corporate Responsibility Sir Christopher Gent Sir Ian Prosser Mr Tom de Swaan Dr Daniel Podolsky * Mr De Swaan will succeed Dr Schmitz as Chairman of the Audit Committee inSeptember 2006. Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 David Mawdsley (020) 8047 5502 Chris Hunter-Ward (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540 Anita Kidgell (020) 8047 5542 Jen Hill (020) 8047 5543 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline